119-HR-8651 Journalist Public Summary

Headline Summary

A bipartisan bill to make medications safer for moms and babies by updating FDA rules and funding research and outreach so more pregnant and breastfeeding women can be included in clinical trials.

What It Does

In plain terms, the bill pushes federal health agencies to include pregnant and lactating women in clinical research and to share clear information about trials and drug safety. It does three big things:

1. Updates and harmonizes FDA human-subject rules with broader HHS policies to make it easier—and safer—to include pregnant women in trials, with a 180‑day deadline after enactment for final regulations.
2. Launches an HHS-led education campaign (with CDC and NIH) so patients, families, and clinicians can easily find and enroll in relevant trials and registries; materials must be posted on a user‑friendly public website. Authorizes $5 million per year for fiscal years 2027–2031.
3. Directs NIH—through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)—to set priorities and fund research on medicines used by pregnant and lactating women, get public input, and report yearly to Congress. Funding is authorized as “such sums as necessary” for fiscal years 2027–2031, and NIH must submit a work plan within 180 days of enactment.

Who’s For It

• Bill sponsors: Rep. Kathy Castor (D‑FL), Rep. Brian Fitzpatrick (R‑PA), and Rep. Lauren Underwood (D‑IL) signal bipartisan backing focused on maternal and infant safety.
• Likely allies: obstetric, pediatric, and maternal‑health organizations that have long called for better evidence on medication use in pregnancy and breastfeeding.
• Research and clinical networks may support clearer rules and funding to answer long‑standing safety and dosing questions.
• Some in the biopharma sector may welcome harmonized regulations that reduce ambiguity about enrolling pregnant and lactating participants.

Who’s Against It

• Some patient‑safety or bioethics advocates may worry about potential risks to fetuses and the need for strong consent and monitoring safeguards.
• Fiscal conservatives may question new federal spending and the open‑ended “such sums as necessary” authorization for NIH research.
• Smaller research sites and sponsors could raise concerns about added costs, liability, or slower trial start‑up while new rules are implemented.
• Privacy advocates may scrutinize how registries and post‑market surveillance handle sensitive health data, even if existing privacy protections remain in place.

What’s Next

Status as of May 4, 2026: The bill was introduced in the House and referred to the Energy and Commerce Committee. Next, the committee may hold hearings and a “markup.” If approved, it would go to a full House vote, then the Senate, and finally to the President.

Key Numbers